City of Hope to Present AI, Precision Medicine, and Immunotherapy Research at AACR 2025 Meeting

City of Hope® is one of the largest and most advanced cancer research and treatment institutions in the United States, consistently ranking highly in the U.S. News & World Report's rankings of cancer hospitals. From April 25 to 30, 2025, researchers from City of Hope will present their latest findings at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. This prestigious event will cover a wide range of topics, including artificial intelligence (AI), precision medicine, immunotherapy, and gene editing, with City of Hope's team participating in over 74 different sessions, including plenary talks, educational courses, mini-symposia, and poster presentations. ### AI and Precision Medicine During the conference, City of Hope's scientists will highlight significant breakthroughs in AI and precision medicine. They have developed a machine learning method to predict how cancer patients will respond to specific treatments, which could revolutionize personalized medicine. This technology analyzes genomic data to provide more accurate predictions, allowing doctors to identify patients who may not respond to certain therapies early on. By doing so, it can help reduce treatment costs and improve patient outcomes. In precision medicine, City of Hope's team will showcase how gene sequencing can be used to classify and diagnose cancers with greater precision. Their research has identified significant genetic variations among patients, enabling more targeted treatment strategies. This approach promises to enhance treatment success rates and minimize side effects, making it a crucial tool in the fight against cancer. ### Immunotherapy Immunotherapy, which harnesses the body's immune system to fight cancer, is another focal point. City of Hope researchers will present their progress in CAR-T cell therapy and tumor microenvironment studies. CAR-T cell therapy involves genetically modifying a patient's T-cells to make them more effective at targeting and destroying cancer cells. Early clinical trials have shown promising results, particularly in treating resistant blood cancers. Additionally, understanding the tumor microenvironment has opened new avenues for immunotherapy, helping to identify and exploit potential targets to boost treatment efficacy. ### Early Diagnosis and Patient Quality of Life City of Hope is also advancing cancer early detection and patient quality of life. They will introduce a blood-based screening technique that can detect specific biomarkers indicative of early-stage cancer. This method could significantly improve early detection, leading to more effective treatments and better survival rates. Furthermore, the team will share insights on how psychological interventions and lifestyle changes can mitigate the side effects of cancer treatments and enhance overall patient well-being. ### Global Collaboration and Future Directions The conference will facilitate in-depth discussions and collaborations between City of Hope's scientists and their international counterparts. These interactions are crucial for accelerating the transition of innovative technologies from the laboratory to clinical practice, ultimately benefiting more cancer patients. Special sessions will invite renowned experts to evaluate City of Hope's research, providing valuable feedback for future work. ### Industry Insiders' Evaluation Industry insiders have hailed City of Hope's contributions to cancer research as exceptional. The institution's leadership in both foundational research and clinical innovation underscores its comprehensive approach to combating cancer. With state-of-the-art facilities and a multidisciplinary team, City of Hope has repeatedly demonstrated its commitment to advancing the field. The wide-ranging participation in the AACR Annual Meeting not only validates the institution's scientific prowess but also reflects its dedication to fostering global cooperation in cancer research. ### Company Profile City of Hope® is a non-profit research and treatment center with a long history of excellence in cancer care. Founded in 1913, it has grown to become a premier institution, known for its innovative and pioneering work in cancer research. The center's holistic approach, combining genetics, immunology, and AI, positions it at the forefront of the scientific and medical community. Their participation in the AACR meeting will further solidify their status as a leader in the global cancer research and treatment landscape. ### Conclusion The 2025 AACR Annual Meeting will be a pivotal platform for City of Hope to showcase its cutting-edge research and collaborative efforts. By highlighting advancements in AI, precision medicine, immunotherapy, and early detection, the institution aims to drive progress in cancer treatment and prevention. The feedback and collaborations generated from the meeting will be instrumental in refining these technologies and bringing them to the clinical forefront, offering hope and improved outcomes for countless cancer patients worldwide.